Currently, there are a number of clinical and molecular markers known to be predictive of prognosis in CLL that can be applied to discriminate patients that are more likely to develop a ...

At least one of the following must be present to determine active CLL. Additionally, certain genetic markers, such as deletion 17p or mutation in the TP53 gene, suggest a more aggressive disease ...

NF-κB as a prognostic factor in chronic lymphocytic leukemia Rel A DNA binding is a powerful prognostic marker in CLL and is also an accurate predictor of duration of response to chemotherapy.

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

Targeted therapies treat chronic lymphocytic leukemia at the molecular level. BTK inhibitors, P13K inhibitors, monoclonal antibodies, and BCL2 agonists are types of targeted therapy for CLL that ...

This study is the first to look at genetic markers in patients with multiple ... Currently, it has been approved to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic ...